• Atea Pharmaceuticals posted a Q2 net loss of $32.93 million, narrowing 11.38% year over year; loss per share improved to $0.41.
• Operating loss narrowed 15.11% to $35.1 million, with R&D expense down 12.78% to $28.15 million.
• G&A expense fell 23.38% to $6.95 million; interest income dropped 50.12% to $2.19 million on lower investment balances.
• Cash and investments slid to $219.47 million at June 30 from $301.83 million at Dec. 31.
• Phase 3 C-BEYOND met primary and secondary endpoints; C-FORWARD topline results are expected early Q1 2027, with an FDA NDA submission targeted for Q2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9808816) on August 12, 2026, and is solely responsible for the information contained therein.